ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Clinical trials for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE trials appear
Sign up with your email to follow new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested in kids with Tough-to-Treat leukemia
Disease control Recruiting nowThis early-stage study aims to find the safest and most effective dose of a drug called venetoclax when given alongside standard chemotherapy. It is for children, teens, and young adults up to age 40 with high-risk blood cancers like leukemia and myelodysplastic syndrome (MDS) th…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Andrew E. Place, MD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New 'Off-the-Shelf' cell therapy trial offers hope for kids with tough leukemia
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new type of CAR T-cell therapy for children and young adults (up to age 21) whose CD19-positive leukemia has come back or hasn't responded to other treatments. The therapy uses immune cells (T-cells) f…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New immune cell therapy targets aggressive blood cancers in kids and adults
Disease control Recruiting nowThis study is testing a new type of personalized immune cell therapy called CD7 CAR T-cells for patients with T-cell blood cancers that have returned or not responded to other treatments. The therapy involves collecting a patient's own immune cells or using donor cells, modifying…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New 'Living Drug' trial targets aggressive blood cancers in kids and adults
Disease control Recruiting nowThis study is testing a new type of personalized cell therapy called CD5 CAR-T for people with T-cell cancers that have come back or not responded to other treatments. Doctors will modify a patient's own immune cells (or cells from a donor) to better target and fight the cancer. …
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Boosting the Body's fight: new therapy aims to recharge Cancer-Killing cells in tough leukemia
Disease control Recruiting nowThis study is for children and young adults (ages 1-39) whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to treatment, and whose previous CAR-T cell therapy stopped working early. Researchers want to see if adding a different type of immune cell, called…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope for kids with relapsed blood cancers: trial tests precision drug cocktail
Disease control Recruiting nowThis trial is testing a new combination of targeted drugs (ruxolitinib and venetoclax) with standard chemotherapy for children and young adults whose leukemia or lymphoma has come back or not responded to prior treatment. It aims to see if this approach is safe and effective for …
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of personalized cell therapy called MB-CART19.1. It is for adults and children (ages 2-70) with certain B-cell blood cancers that have come back or have not responded to standard treatments. Doctors will col…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for kids with tough blood cancers: trial tests precision medicine combo
Disease control Recruiting nowThis trial is testing a new combination of drugs for children and young adults whose leukemia or lymphoma has come back or hasn't responded to standard treatments. It specifically targets cancers with certain genetic changes. The goal is to see if adding a targeted drug called tr…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New Two-Pronged cell therapy offers hope for kids with tough leukemia
Disease control Recruiting nowThis early-stage trial is testing a new two-part cell therapy for children and young adults whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments. The therapy involves giving specially engineered immune cells (CAR-T cells) from a donor, f…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New CAR-T therapy battle: Two-Pronged attack vs. transplant bridge for tough leukemia
Disease control Recruiting nowThis study is comparing two advanced cell therapy approaches for patients with B-cell acute lymphoblastic leukemia that has returned or not responded to previous treatments. One approach uses two different CAR-T cell infusions in sequence, while the other uses one CAR-T cell infu…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC
-
New hope for incurable blood cancers: experimental CAR-T therapy enters trial
Disease control Recruiting nowThis study is testing a new type of personalized immune cell therapy, called CD5-CAR T cells, for people with aggressive T-cell blood cancers that have come back or not responded to standard treatments. The main goals are to find a safe and effective dose and to see if the therap…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC